TXMD stock: buy or sell?
September 20th, 2019
TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Should I buy TXMD stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, TherapeuticsMD stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is TherapeuticsMD stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we detected 9 ratings published for TXMD stock in the last month. The general sentiment of these ratings is bullish for TXMD stock, with 7 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-15||Jefferies Financial Group||n/a||n/a|
|2019-6-11||JPMorgan Chase & Co.||n/a||Overweight|
|2019-5-7||Jefferies Financial Group||n/a||Hold|
TXMD stock analysis
TherapeuticsMD stayed steady a neutral 0.00% and closed at $3.71.
TherapeuticsMD stayed stable a neutral 0.00% and closed at $3.71. From a daily perspective, TXMD is in a short term uptrend after plotting its last bottom ($2.73, on Sep/4) higher than the previous bottom, and its last top ($3.98, yesterday) also over the previous top. Now trading in between its last bottom and last top TXMD might consolidate in a plain range, waiting to break out over $3.98 or down under $2.73. Since price and SMA100d lines crossed up on September/9, TXMD climbed $0.84 (29.27%).
TherapeuticsMD ended this week at $3.71 and climbed a dazzling 8.48%. By mid August TXMD collapsed a scary -8.39% in just one week.
TXMD stock price history
TXMD IPO was on October 5th, 2017 at $5.15 per share1. Since then, TXMD stock declined a -28.00%, with a yearly average of -28.00%.
1: Adjusted price after possible price splits or reverse-splits.
TXMD stock historical price chart
TXMD stock reached 52-week highs at $6.94, and all-time highs 2018-06-08 with a price of 7.66.
TXMD stock price target is $8.70Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 9 price targets for TherapeuticsMD stock published in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-15||Jefferies Financial Group||Lowers Target||$4.00||$3.00||-25%|
|2019-6-11||JPMorgan Chase & Co.||Lowers Target||$8.00||$6.00||-25%|
|2019-5-7||Jefferies Financial Group||Lowers Target||$5.00||$4.00||-20%|
|2019-2-11||Oppenheimer||Set Price Target||n/a||$14.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, TherapeuticsMD matched the estimates of the experts and reported an EPS of $-0.17 per share. As soon as we get its actual EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, TherapeuticsMD annual sales declined an awful -4.04% to $16.10 M USD from $16.78 marked in 2017. Improving that, its earnings margin (compared to revenues) plunged to -823.73%, that is $-132.62 million.
|2013||$8.78 M||-||$-28.42 M-323.7%||-|
|2014||$15 M||71.14%||$-54.22 M-360.8%||90.77%|
|2015||$20 M||34.05%||$-85.08 M-422.4%||56.92%|
|2016||$19 M||-3.90%||$-89.88 M-464.3%||5.64%|
|2017||$17 M||-13.32%||$-76.93 M-458.5%||-14.41%|
|2018||$16 M||-4.04%||$-132.62 M-823.7%||72.40%|
Quarterly financial resultsTherapeuticsMD posted $5.09 million in revenues for 2018-Q4, a 46.52% improvement compared to previous quarter. Reported quarter income marked $-39.39 million with a profit margin of -773.96%. Profit margin skyrocketed a 251.08% compared to previous quarter when profit margin was -1,025.04%. When comparing sales to same quarter last year, TherapeuticsMD sales marked an exceptional growth and boosted a 23.41%.
|2017-Q1||$4 M||-||$-21.16 M-530.3%||-|
|2017-Q2||$4 M||6.52%||$-19.68 M-463.1%||-6.99%|
|2017-Q3||$4 M||3.94%||$-14.66 M-332.0%||-25.48%|
|2017-Q4||$4 M||-6.64%||$-21.43 M-519.5%||46.12%|
|2018-Q1||$4 M||-8.51%||$-24.40 M-646.7%||13.88%|
|2018-Q2||$4 M||-0.28%||$-33.22 M-882.8%||36.13%|
|2018-Q3||$3 M||-7.69%||$-35.61 M-1025.0%||7.18%|
|2018-Q4||$5 M||46.52%||$-39.39 M-774.0%||10.63%|
TherapeuticsMD ownershipWhen you are planning to invest in a company, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For TherapeuticsMD, 17.76% of all outstanding shares are owned by its staff.
In case of TherapeuticsMD stock, 78.61% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for TXMD stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to TherapeuticsMD:
|Market cap||$894.9 M||$106.1 B||$70.0 M||$443.8 M||$541.9 M|
|Total shares||241.2 M||1,480.0 M||59.3 M||33.9 M||40.4 M|
|Float shares||198.7 M||1,480.0 M||31.0 M||15.8 M||26.6 M|
|- Institutional holdings (%)||78.6%||71.9%||54.2%||121.2%||86.6%|
|- Insider holdings (%)||17.8%||0.1%||1.3%||2.1%||28.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$3.39 - $3.77|
|Average true range||$0.25|
|50d mov avg||$2.73|
|100d mov avg||$2.89|
|200d mov avg||$3.89|
TherapeuticsMD performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For TherapeuticsMD, the comparison is made against AbbVie, Agile Therapeutics, AMAG Pharmaceuticals, Lannett and Pfizer.